azelaic acid + tranexamic acid

Azelaic acid + tranexamic acid is an investigational fixed-dose combination topical formulation being developed for the treatment of melasma. The formulation typically contains 12% azelaic acid and 5% tranexamic acid. Azelaic acid is a dicarboxylic acid that inhibits melanin synthesis by targeting tyrosinase activity in melanocytes. Tranexamic acid is an antifibrinolytic agent that reduces melanin production by inhibiting melanocyte activation through the plasminogen-keratinocyte pathway. The combination is currently being evaluated in clinical trials by the University of Guadalajara to assess its efficacy in reducing melasma severity and improving patient quality of life.

Other names

azelaic acid 12% / tranexamic acid 5% topical formulation